These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17346156)

  • 21. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.
    Mao Q; Unadkat JD
    AAPS J; 2015 Jan; 17(1):65-82. PubMed ID: 25236865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
    Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
    Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
    Cascorbi I; Haenisch S
    Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.
    de Wolf C; Jansen R; Yamaguchi H; de Haas M; van de Wetering K; Wijnholds J; Beijnen J; Borst P
    Mol Cancer Ther; 2008 Sep; 7(9):3092-102. PubMed ID: 18765824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABCG2 transporter: therapeutic and physiologic implications in veterinary species.
    Mealey KL
    J Vet Pharmacol Ther; 2012 Apr; 35(2):105-12. PubMed ID: 21645015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
    Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
    Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
    Meyer zu Schwabedissen HE; Kroemer HK
    Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABCG2: determining its relevance in clinical drug resistance.
    Robey RW; Polgar O; Deeken J; To KW; Bates SE
    Cancer Metastasis Rev; 2007 Mar; 26(1):39-57. PubMed ID: 17323127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABCG2: recent discovery of potent and highly selective inhibitors.
    Lecerf-Schmidt F; Peres B; Valdameri G; Gauthier C; Winter E; Payen L; Di Pietro A; Boumendjel A
    Future Med Chem; 2013 Jun; 5(9):1037-45. PubMed ID: 23734686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemistry and pharmacology of the human multidrug resistance gene product, ABCG2.
    Zhang JT
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):531-41. PubMed ID: 17767037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter.
    Telbisz Á; Hegedüs C; Özvegy-Laczka C; Goda K; Várady G; Takáts Z; Szabó E; Sorrentino BP; Váradi A; Sarkadi B
    Eur J Pharm Sci; 2012 Jan; 45(1-2):101-9. PubMed ID: 22115866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New use for an old drug: inhibiting ABCG2 with sorafenib.
    Wei Y; Ma Y; Zhao Q; Ren Z; Li Y; Hou T; Peng H
    Mol Cancer Ther; 2012 Aug; 11(8):1693-702. PubMed ID: 22593228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites.
    Telbisz Á; Hegedüs C; Váradi A; Sarkadi B; Özvegy-Laczka C
    Drug Metab Dispos; 2014 Apr; 42(4):575-85. PubMed ID: 24384916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
    Robey RW; Obrzut T; Shukla S; Polgar O; Macalou S; Bahr JC; Di Pietro A; Ambudkar SV; Bates SE
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):575-83. PubMed ID: 19132374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated Expression of Nrf-2 and ABCG2 Involved in Multi-drug Resistance of Lung Cancer SP Cells.
    Yang B; Ma YF; Liu Y
    Drug Res (Stuttg); 2015 Oct; 65(10):526-31. PubMed ID: 25368906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.